Sid Kerkar

Sid Kerkar

Company: EXUMA Biotechnology

Job title: Vice President, Research & Development

Seminars:

Optimizing the In Vivo Approach: Considerations for Safety & Tolerability 1:30 pm

• How do we improve the safety and tolerability of in vivo therapies? • To what extent do we have to worry about off-target effects? • How do we circumnavigate the issue of immunogenicity and integration?Read more

day: Day Two

Optimizing the In Vivo Approach: Considerations for Safety & Tolerability 1:30 pm

• How do we improve the safety and tolerability of in vivo therapies? • To what extent do we have to worry about off-target effects? • How do we circumnavigate the issue of immunogenicity and integration?Read more

day: Day 2, Track A pm

Industry Leader’s Fireside Chat: In Vivo Engineering of Therapeutic Cells as the Future of Cell & Gene Therapy 9:30 am

• Answering the question: what has inspired the move from ex vivo to in vivo therapies? • Outlining the advantages and opportunities that in vivo cell and gene therapies offer over current generations • Discussing the next steps to streamline pre-clinical development to fast-track in vivo therapies to the clinicRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.